BOTULAX® 300u
Name: BOTULAX® 300u
Manufacturer: Hugel, Inc.
Active Substance(s): BOTULINUM TOXIN TYPE A
Strength: 300u
Pack Size: 1 x 300u Vial (Powder)
BOTULAX® 300u is a 300-unit lyophilized powder formulation of purified Clostridium botulinum toxin type A (letibotulinumtoxinA), manufactured by Hugel, Inc. in South Korea. It acts by blocking acetylcholine release at the neuromuscular junction, producing temporary, reversible muscle relaxation in the treatment area.
Specifications
Description
Name: BOTULAX® 300u
Manufacturer: Hugel, Inc.
Active Substance(s): BOTULINUM TOXIN TYPE A
Strength: 300u
Pack Size: 1 x 300u Vial (Powder)
BOTULAX® 300u
BOTULAX® 300u is a purified botulinum toxin type A formulation by Hugel, Inc. in South Korea, supplied as a 300-unit lyophilized powder vial that requires reconstitution before use, per product labeling. Used by licensed healthcare professionals in aesthetic and, where locally authorized, therapeutic contexts, it acts by temporarily blocking acetylcholine release at the neuromuscular junction, reducing muscle activity in the treatment area. Licensed practitioners seeking to buy BOTULAX® 300u online for permitted professional use are encouraged to contact the Direct Doctor Supply support team for sourcing guidance and documentation.
Product Specifications
- Strength: 300 units (300u)
- Active Substance: Purified Clostridium botulinum toxin type A
- Dosage Form: Sterile powder for reconstitution
- Manufacturer: Hugel, Inc.
- Package Content: 1 × 300u vial (powder)
- Country of Origin: South Korea
- Brand: BOTULAX®
- Therapeutic Applications: Wrinkle reduction and therapeutic applications according to clinical indication
- Dimensions: Width: 50 mm | Height: 80 mm | Length: 40 mm
What Is BOTULAX® 300u?
BOTULAX® is a brand of botulinum toxin type A by Hugel, Inc., a South Korean company active in medical aesthetics and pharmaceutical biologics. [5] The active ingredient is letibotulinumtoxinA, derived from the CBFC26 strain of Clostridium botulinum toxin type A, and is registered with the Korean MFDS for specified presentations. [4] Regulatory filings identify the CBFC26 strain as the basis for BOTULAX® formulations in Korea. [3][4]
The 300u vial format provides licensed practitioners with a higher unit content suited to multi-zone treatment planning, larger treatment areas, or therapeutic applications requiring careful unit distribution. Unit requirements are determined by the treating practitioner based on patient anatomy, clinical indication, muscle characteristics, and jurisdiction-specific guidance.
BOTULAX® 300u requires reconstitution before use, per product labeling. As a potent biologic, preparation and administration are limited to trained, licensed healthcare professionals working within applicable pharmaceutical regulations and institutional protocols.
In professional aesthetic practice, botulinum toxin type A is associated with softening dynamic facial wrinkles — lines that form from repeated muscle contractions over time. Correct administration by a qualified practitioner may reduce the appearance of treatment-area lines. [1]
Mechanism of Action
BOTULAX® 300u works by inhibiting acetylcholine release at the presynaptic neuromuscular junction, producing temporary, reversible relaxation of targeted muscles. [1] The toxin cleaves SNAP-25, a SNARE protein required for neurotransmitter vesicle fusion, preventing the muscle from contracting normally in the treatment area. This mechanism supports wrinkle reduction in dynamic facial lines and underpins therapeutic applications where controlled reduction of muscle activity is clinically appropriate. [3]
The effect is reversible as new nerve terminals develop over time, gradually restoring acetylcholine release and muscle activity. Botulinum toxin type A, as a class, is generally associated with a clinical effect that begins within days of injection and lasts approximately 3–4 months, though the duration varies by patient, dose, treatment area, and clinical protocols. [1] Specific dilution protocols and storage windows remain dependent on institutional guidelines and individual practitioner judgment.
Therapeutic Applications & Indications
BOTULAX® 300u is used by licensed healthcare professionals in aesthetic and, where locally authorized, therapeutic contexts. In aesthetic medicine, it is associated with dynamic facial wrinkle reduction, particularly of glabellar lines, forehead lines, and lateral canthal lines (crow’s feet), which are caused by repetitive muscle contractions. For practitioners comparing botulinum toxins, the 300u vial format may be relevant when managing multi-zone treatment plans or higher unit-allocation needs. [1]
BOTULAX® (letibotulinumtoxinA) has been studied in clinical trials for both aesthetic and therapeutic indications. A Phase 3 clinical trial evaluated its safety and efficacy for post-stroke upper limb spasticity, supporting its use in therapeutic contexts where a temporary reduction in muscle activity is indicated. [2] BOTULAX®-specific indications remain subject to country-specific labeling and local regulatory authorization; practitioners must verify which indications are currently approved in their jurisdiction before clinical use. [4]
Prior to treatment, practitioners should conduct a thorough patient assessment that covers anatomical evaluation, neuromuscular history, contraindication screening, current medications, and treatment expectations. Informed consent should address expected onset, typical duration, potential adverse effects, and maintenance considerations. Administration is restricted to licensed professionals with formal training in the use of botulinum toxin.
Reconstitution & Dilution Protocol
BOTULAX® 300u requires reconstitution before use, per product labeling. The lyophilized powder is combined with sterile saline, with the diluent volume selected to achieve the desired unit concentration per milliliter. A reduced volume produces a more concentrated solution; a greater volume yields a less concentrated preparation. Dilution ratios are adjusted based on treatment area, muscle mass, injection technique, and therapeutic objective.
A BOTULAX® dilution chart may assist practitioners in calculating the number of units per 0.1 mL or per mL after reconstitution. It is a reference tool only, as specific protocols and storage windows are institutional and practitioner-dependent, and no chart substitutes for current manufacturer guidance or formal clinical training. Practitioners who check for wholesale buying options should confirm that procurement includes full cold-chain documentation, as verified storage history directly affects product integrity.
Safe preparation requires rigorous aseptic technique throughout. The vial should be visually inspected before use, the diluent confirmed as appropriate for injection, the stopper disinfected before needle entry, and the reconstituted solution handled carefully to avoid foaming, contamination, or dosing inaccuracy.
Safety & Adverse Reactions
BOTULAX® 300u must be prepared and administered exclusively by licensed healthcare professionals. Safe use depends on appropriate patient selection, accurate dilution and dosing, precise anatomical placement, and verified product handling throughout. A Phase 3 clinical trial evaluating letibotulinumtoxinA for glabellar line treatment reported a safety profile consistent with the botulinum toxin type A class, with most adverse events mild and localized. [1]
Commonly reported reactions include localized redness, swelling, bruising, tenderness, and headache. Facial asymmetry or unintended muscle weakness may occur if placement or dosing is imprecise. Serious adverse events are uncommon but may include systemic spread of toxin effects, presenting as difficulty swallowing, speech impairment, respiratory difficulty, or generalized muscle weakness. [1]
Contraindications include hypersensitivity to botulinum toxin or any formulation component, active infection at the injection site, known neuromuscular disorders, and pregnancy or lactation where local guidance restricts use. Any condition in which neuromuscular blockade poses additional clinical risk requires careful pre-treatment evaluation.
Legal & Regulatory Status
BOTULAX® 300u is manufactured by Hugel, Inc. in South Korea and registered with the Korean MFDS as a biological drug product containing Clostridium botulinum toxin type A, with indications specified for BOTULAX® presentations in Korea. [4][5] Practitioners who purchase botulinum toxins through professional channels should confirm that all products meet the applicable regulatory and documentation standards in their jurisdiction.
Regulatory status varies by jurisdiction. Licensed practitioners must confirm whether BOTULAX® 300u is authorized in their market before procurement or clinical use, as requirements differ across countries regarding registration, importation, prescription classification, and professional training standards.
Practitioners should independently verify applicable local regulations, confirm authorized sourcing channels, inspect package integrity and storage documentation, and review current product labeling before clinical use.
Where Can Licensed Practitioners Buy BOTULAX® 300u Online?
When buying online, practitioners should confirm the supplier provides a certificate of analysis, verifiable LOT numbers, documented storage history, and current regulatory authorization for their jurisdiction. These standards apply regardless of vial size or order volume.
Direct Doctor Supply support team can provide guidance on documentation expectations and professional account eligibility for practitioners looking to buy BOTULAX® through verified channels. Contact the Direct Doctor Supply support team directly to discuss procurement context, professional eligibility, and available documentation resources.
References
- Mueller DS, Prinz V, Adelglass J, et al. Efficacy and safety of letibotulinum toxin A in the treatment of glabellar lines: a randomized, double-blind, multicenter, placebo-controlled phase 3 study. Aesthetic Surgery Journal. 2022. https://pubmed.ncbi.nlm.nih.gov/35092418/
- Do KH, Chun MH, Paik NJ, et al. Safety and efficacy of letibotulinumtoxinA (BOTULAX®) in treatment of post stroke upper limb spasticity: a randomized, double blind, multi-center, phase III clinical trial. Clinical Rehabilitation. 2017. https://pubmed.ncbi.nlm.nih.gov/28118733/
- Bravo M, Vogel K, Sternfels W, Touchet N, Turegano M. Botulax and the US development. Dermatological Reviews. 2022. https://onlinelibrary.wiley.com/doi/abs/10.1002/der2.162
- Ministry of Food and Drug Safety (Korea). Biological Products: Hugel, Inc. 2016. https://www.mfds.go.kr/eng/brd/m_30/view.do?seq=69800
- Hugel, Inc. HUGEL. https://www.hugel-inc.com/
All content on this website is intended for informational purposes and does not constitute medical advice.
Important Information
Warning! The product is intended solely for professional use in a medical environment and under professional supervision. The product is supplied to medical professionals who specialize in aesthetic medicine (plastic surgery, facial treatments) and work under individual medical licenses as aestheticians or in dedicated clinics. Unprofessional use by individuals without a medical background may lead to severe adverse effects and health harm.
Direct Doctor Supply sources its inventory only through authorized distribution channels, so every order arrives sealed in the manufacturer’s original packaging. Our sourcing standards and tracked delivery mean you receive authentic original products every time.
Content prepared by Direct Doctor Supply’s editorial team.
Sourcing and accuracy for this page follow our Editorial Policy: claims are cross-checked against clinical literature, regulatory filings, and manufacturer specifications before anything is published.

